Table 1 Baseline characteristics of the included studies
Article | Country | Number (M/F)a | Age Mean ± SDb/Median (range) (yc) | TSd | Markers | Adjuvant therapy | STe | Rate (+)f | OMg | HRh estimate | CSi | MAj |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kust 2016 [33] | Croatia | 82(49/33) | Mean:66 ± 9.6 | I-III | CK20 | Post-OPk CTl for III and part of II | Pre-OP | 22 (26.83%) | OSm DFSn | Data extrapolated | Yes | No |
Liu 2013 [28] | China | 92(60/32) | Mean:66 ± 9.6 | I-III | CK20 | _ | Pre-OP | 31 (25%) | OS DFS | Reported in text | Yes | Yes |
Liu 2013 (1) [28] | China | 41(NR) | NRo | II | CK20 | Without | _ | NR | OS DFS | Reported in text | Yes | Yes |
Liu 2013 (2) [28] | China | 51(NR) | NR | III | CK20 | Post-OP CT | _ | NR | OS DFS | Reported in text | Yes | Yes |
Yokobori (1) 2013 [29] | Japan | Training: 151(86/65) | Mean:66.76 ± 11.02 | II | PLS3 | Without | Pre-OP | 33 (21.85%) | OS DFS | Reported in text | Yes | Yes |
Yokobori (2) 2013 [29] | Japan | Training: 131(75/56) | Mean:66.76 ± 11.02 | III | PLS3 | Post-OP CT | Pre-OP | 38 (29%) | OS DFS | Reported in text | Yes | Yes |
Yokobori (3) 2013 [29] | Japan | Validation: 158(96/62) | Mean:67.51 ± 11.08 | II | PLS3 | Without | Pre-OP | 35 (22.15%) | OS DFS | Reported in text | Yes | Yes |
Yokobori (4) 2013 [29] | Japan | Validation: 103(63/40) | Mean:67.51 ± 11.08 | III | PLS3 | Post-OP CT | Pre-OP | 30 (29.12%) | OS DFS | Reported in text | Yes | Yes |
Shimada (1) 2012 [19] | Japan | 111(60/51) | Median:68(27–82) | II | CEA, CK19, CK20, CD133 | Without | Post-OP | 63 (56.76%) | OS DFS | Reported in text | Yes | Yes |
Shimada (2) 2012 [19] | Japan | 86(47/39) | Median:68(27–82) | III | CEA, CK19, CK20, CD133 | Post-OP CT | Post-OP | 61 (70.93%) | OS DFS | Reported in text | Yes | Yes |
Iinuma (1) 2011 [30] | Japan | Training: 420(224/196) | Mean:66.0 ± 12.4 | I-III | CEA, CK19, CK20, CD133 | _ | Post-OP | 106(25.24%) | OS DFS | Reported in text | Yes | Yes |
Iinuma (1–1) 2011 [30] | Japan | Training: 176(NR) | NR | II | CEA, CK19, CK20, CD133 | Without | _ | NR | OS DFS | Reported in text | Yes | Yes |
Iinuma (1–2) 2011 [30] | Japan | Training:150(NR) | NR | III | CEA, CK19, CK20, CD133 | Post-OP CT | _ | NR | OS DFS | Reported in text | Yes | Yes |
Iinuma (2) 2011 [30] | Japan | Validation: 315(175/140) | Mean:66.0 ± 12.4 | I-III | CEA, CK19, CK20, CD133 | _ | Post-OP | 75(23.81%) | OS DFS | Reported in text | Yes | Yes |
Iinuma (2–1) 2011 [30] | Japan | Validation: 143(NR) | NR | II | CEA, CK19, CK20, CD133 | Without | _ | NR | OS DFS | Reported in text | Yes | Yes |
Iinuma (2–2) 2011 [30] | Japan | Validation: 97(NR) | NR | III | CEA, CK19, CK20, CD133 | Post-OP CT | _ | NR | OS DFS | Reported in text | Yes | Yes |
Uen 2008 [31] | China | 438(234/204) | NR | I-III | CK19, CK20, CEA, hTERT | Post-OP CT for III and part of II | Post-OP (1 Wp) | 137 (31.27%) | DFS | Reported in text | Yes | Yes |
Barreto 2007 [32] | UK | 113(NR) | Mean:67 | I-III | CEA, CK20 | Post-OP CT for III and part of II | Post-OP (24 hq) | 34 (30.09%) | DFS | Reported in text | Yes | Yes |
Koch 2006 [33] | Germany | 90(59/31) | Mean:66.1 | II | CK20 | Post-OP CT for rectal cancer | Post-OP | 28 (31.1%) | OS DFS | Reported in text | Yes | No |
Lloyd 2006 [34] | Australia | 125 (74/51) | Median:74 (43–95) | I-II | CK20, CEA, EphB4, LAMγ2, MAT | Without | Pre-OP | 5 (4%) | DFS | Data extrapolated | Yes | No |
Sadahrio 2005 [35] | Japan | 100(NR) | NR | I-III | CEA | NR | Intra-OP | 39 (39%) | OS DFS | Data extrapolated | Yes | Yes |
Bessa 2003 [36] | Spain | 66 (23/43) | Median:73 | I-III | CEA | Post-OP CT for III and part of II | Post-OP | 36 (54.55%) | OS DFS | Reported in text | Yes | Yes |
Ito 2002 [37] | Japan | 99(62/37) | NR | I-III | CEA | NR | Post-OP | 26 (26.26%) | DFS | Data extrapolated | Yes | No |